OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, promoted Sheela Mohan-Peterson, JD, MS, to Chief Legal and Compliance Officer, effective August 24, 2015. In this role, Ms. Mohan-Peterson will advise the Company’s officers and Board of Directors on all major legal matters and continue to lead the Company’s intellectual property portfolio and global legal strategy.

“Sheela has provided valuable leadership and counsel, which has contributed to the growth and success of OncoSec over the past year,” said Punit Dhillon, President and CEO of OncoSec. “Her extensive legal expertise has allowed us to expand our intellectual property portfolio by leveraging our R&D and preclinical activities. I expect Sheela will continue to balance risks and opportunities as we navigate new business growth opportunities in this expanded role.”

Ms. Mohan-Peterson has spent 29 years working in the pharmaceutical and biotech industries and joined OncoSec in September 2014, serving as General Counsel and Corporate Secretary. She was most recently a Senior Patent Counsel at Merck & Co., Inc. Ms. Mohan-Peterson also held patent counsel positions at several companies including: Schering-Plough Biopharma, DNAX Research Institute, Incyte Genomics, and Roche Bioscience. She received her bachelor’s degree in Biology from Washington University in St. Louis, her master’s degree in Biology from Rutgers University, and her law degree from Peninsula (now Lincoln) University (CA). (Original Source)

Shares of OncoSec Medical Inc closed last Friday at $5.76. ONCS has a 1-year high of $13.20 and a 1-year low of $4.00. The stock’s 50-day moving average is $5.92 and its 200-day moving average is $6.52.

On the ratings front, OncoSec Medical has been the subject of a number of recent research reports. In a report issued on August 19, H.C. Wainwright analyst Mark Breidenbach initiated coverage with a Buy rating on ONCS and a price target of $25, which represents a potential upside of 334.0% from where the stock is currently trading. Separately, on August 18, Maxim Group’s Jason Kolbert reiterated a Buy rating on the stock and has a price target of $17.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Mark Breidenbach and Jason Kolbert have a total average return of -27.1% and -10.6% respectively. Breidenbach has a success rate of 0.0% and is ranked #3503 out of 3737 analysts, while Kolbert has a success rate of 29.8% and is ranked #3723.

OncoSec Medical Inc is a hybrid device and gene therapy biotechnology company. It is engaged in designing, developing and commercializing medical approaches for treatment of cancer.